Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Revenue (2022 - 2025)

Historic Revenue for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $171.0 million.

  • Axsome Therapeutics' Revenue rose 6321.95% to $171.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $561.3 million, marking a year-over-year increase of 6582.99%. This contributed to the annual value of $385.7 million for FY2024, which is 4253.25% up from last year.
  • Axsome Therapeutics' Revenue amounted to $171.0 million in Q3 2025, which was up 6321.95% from $150.0 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Revenue registered a high of $171.0 million during Q3 2025, and its lowest value of $8.8 million during Q2 2022.
  • In the last 4 years, Axsome Therapeutics' Revenue had a median value of $81.1 million in 2024 and averaged $82.1 million.
  • Per our database at Business Quant, Axsome Therapeutics' Revenue surged by 42947.85% in 2023 and then tumbled by 2069.98% in 2024.
  • Axsome Therapeutics' Revenue (Quarter) stood at $24.4 million in 2022, then skyrocketed by 193.5% to $71.5 million in 2023, then skyrocketed by 66.04% to $118.8 million in 2024, then soared by 43.97% to $171.0 million in 2025.
  • Its last three reported values are $171.0 million in Q3 2025, $150.0 million for Q2 2025, and $121.5 million during Q1 2025.